EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients

Lucia Di Nardo, Laura Del Regno, Alessandro Di Stefani, Maria Mannino, Barbara Fossati, Silvia Catapano, Laura Quattrini, Cristina Pellegrini, Alessio Cortellini iD, Alessandro Parisi, Ettore Capoluongo, Chiara Autilio und 2 weitere

Experimental Dermatology · 2023

DOI: 10.1111/exd.14901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Lucia Di Nardo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Melanoma, Circulating Tumor DNA, Proto-Oncogene Proteins B-raf, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the introduction of targeted (BRAFi/MEKi) and immune checkpoint inhibitors (ICIs) has significantly reduced the recurrence rate and improved the overall survival (OS) of patients with Stage III and IV melanoma, only a percentage will benefit of durable disease control. The aim of this study was to examine whether the levels of circulating tumour DNA (ctDNA) in plasma of advanced melanoma patients undergoing BRAFi/MEKi or ICIs vary according to the patients' survival outcomes (i.e. progression‐free survival (PFS) and OS) and disease progression. Plasma samples of Stage III‐IV melanoma patients were collected at baseline (treatment initiation) and thereafter every 3 months. Circulating BRAF V600E/K and NRAS Q61R/K mutations were analysed through droplet digital PCR (ddPCR, Bio‐Rad) in a total of 177 plasma samples from 48 melanoma patients (19 Stage III, 29 Stage IV). Baseline ctDNA concentration was significantly associated with OS (HR = 1.003, 95% CI = 1.000–1.006, p = 0.043) and PFS (HR = 1.004, 95% CI = 1.000–1.007, p = 0.029) independent of clinical‐prognostic confounders. For each unit increase in the ∆ctDNA (concentration difference between the last follow‐up and baseline) there was a 24% increased risk of disease progression, irrespective of treatment type and stage at diagnosis (OR = 1.24, 95% CI = 1.03–1.49, p = 0.020, AUC = 0.93). Patients with reduction of ctDNA level from baseline to the last follow‐up had longer OS (HR = 0.14; 95% CI = 0.05–0.44, p = 0.001) and PFS (HR = 0.08; 95% CI = 0.03–0.27, p < 0.0001) compared to patients with increased ctDNA, including adjustment for confounding factors. Our findings suggest that variation of ctDNA over time during melanoma treatment reflects the clinical outcome and tumour response to therapy and might be helpful in clinical monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaCirculating Tumor DNAProto-Oncogene Proteins B-rafSkin NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultImmune Checkpoint InhibitorsMutationDisease ProgressionProgression-Free SurvivalNeoplasm StagingProtein Kinase InhibitorsAged, 80 and overGTP PhosphohydrolasesMembrane Proteins

Stichwörter der Autor:innen

circulating tumour DNAfollow-up studiesimmune checkpoint inhibitorsmelanomaprogression-free survival

Substanzen

Circulating Tumor DNAProto-Oncogene Proteins B-rafBRAF protein, humanImmune Checkpoint InhibitorsNRAS protein, humanProtein Kinase InhibitorsGTP PhosphohydrolasesMembrane Proteins

Autor:innen und Institutionen

  • Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A, Gemelli - IRCCS, Rome, Italy.
  • Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Medical Oncology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Department of Surgery & Cancer, Imperial College London, London, UK.
  • Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.

ORCID-Profile: Alessio Cortellini

Zitieren

APA

Di Nardo, L., Del Regno, L., Di Stefani, A., Mannino, M., Fossati, B., Catapano, S., Quattrini, L., Pellegrini, C., Cortellini, A., Parisi, A., Capoluongo, E., Autilio, C., Fargnoli, M. C., & Peris, K. (2023). The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients. Experimental Dermatology. https://doi.org/10.1111/exd.14901

Vancouver

Di Nardo L, Del Regno L, Di Stefani A, Mannino M, Fossati B, Catapano S, et al. The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients. Experimental Dermatology. 2023. doi:10.1111/exd.14901

BibTeX
@article{DiNardo2023,
  author = {Di Nardo, Lucia and Del Regno, Laura and Di Stefani, Alessandro and Mannino, Maria and Fossati, Barbara and Catapano, Silvia and Quattrini, Laura and Pellegrini, Cristina and Cortellini, Alessio and Parisi, Alessandro and Capoluongo, Ettore and Autilio, Chiara and Fargnoli, Maria Concetta and Peris, Ketty},
  title = {The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14901}
}
Kostenlos starten →